Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus GASTROCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus GASTROCROM.
ACUVUE THERAVISION WITH KETOTIFEN vs GASTROCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Mast Cell Stabilizer